Statin Therapy Side Effects and Management

Introduction to Statin Side Effects

The American College of Cardiology states that statins are generally safe and well-tolerated medications, but they can cause muscle-related symptoms, modest increases in diabetes risk, and rarely, liver enzyme elevations—though the cardiovascular benefits far outweigh these risks in appropriate patients 1, 2, 3

Muscle symptoms are the most frequent side effect, occurring in 1-5% of patients in clinical trials but 5-20% in real-world practice, according to the American College of Cardiology 1, 2, 3
Myalgia (muscle pain/aches) is the most common presentation, typically bilateral, involving proximal muscles, with normal creatine kinase (CK) levels, as reported by the American College of Cardiology 4, 2
Symptoms usually begin within weeks to months after starting therapy and resolve after discontinuation, as noted by the American College of Cardiology 2
Myositis/myopathy (elevated CK with concerning symptoms or objective weakness) is rare, according to the American College of Cardiology 1, 2
Rhabdomyolysis (CK >10 times upper limit of normal with renal injury) is exceedingly rare and typically occurs only with multiple predisposing factors, as stated by the American College of Cardiology 2
Statin-associated autoimmune myopathy (with HMGCR antibodies and incomplete resolution) is rare, according to the American College of Cardiology 2

Advanced age (especially >80 years), with women at higher risk than men, is a risk factor for muscle symptoms, as reported by the American College of Cardiology 4
Small body frame and frailty are risk factors for muscle symptoms, according to the American College of Cardiology 5
Low body mass index is a risk factor for muscle symptoms, as noted by the American College of Cardiology 2
Multisystem disease (particularly chronic renal insufficiency from diabetes) is a risk factor for muscle symptoms, according to the American College of Cardiology 4, 5
Polypharmacy and drug interactions (CYP3A4 inhibitors, OATP1B1 inhibitors, cyclosporine, gemfibrozil, macrolide antibiotics, antifungal agents) are risk factors for muscle symptoms, as reported by the American College of Cardiology 4, 2, 5
Asian ancestry is a risk factor for muscle symptoms, according to the American College of Cardiology 2
Excess alcohol consumption is a risk factor for muscle symptoms, as noted by the American College of Cardiology 2
High levels of physical activity and trauma are risk factors for muscle symptoms, according to the American College of Cardiology 2
Perioperative periods are a risk factor for muscle symptoms, as reported by the American College of Cardiology 5
Higher statin doses are a risk factor for muscle symptoms, according to the American College of Cardiology 5

Statins modestly increase the risk of developing type 2 diabetes in susceptible individuals, but this should NOT be cause for discontinuation, as stated by the American College of Cardiology 1, 2, 3
Risk is higher in patients with pre-existing diabetes risk factors: BMI ≥30, fasting glucose ≥100 mg/dL, metabolic syndrome, or HbA1c ≥6%, according to the American College of Cardiology 2
Continue statin therapy if diabetes develops, with added emphasis on adherence, moderate-intensity physical activity, healthy dietary patterns, and modest weight loss, as recommended by the American College of Cardiology 1, 3

Transaminase elevation (>3 times upper limit of normal) is infrequent, according to the American College of Cardiology 2
Hepatic failure is rare, as noted by the American College of Cardiology 2
Statins can be used in patients with chronic, stable liver disease (including non-alcoholic fatty liver disease) after obtaining baseline measurements and establishing monitoring schedules, as stated by the American College of Cardiology 1, 3

Evaluate muscle symptoms at baseline, 6-12 weeks after starting therapy, and at each follow-up visit, as recommended by the American College of Cardiology 4
Measure CK levels only in patients with severe muscle symptoms or objective muscle weakness—NOT routinely, according to the American College of Cardiology 1, 3
Measure liver transaminases (ALT/AST) initially, at approximately 12 weeks, then annually or if symptoms suggest hepatotoxicity, as recommended by the American College of Cardiology 4, 1, 3

Use a "reassess, rediscuss, and rechallenge" approach—the majority of patients can successfully tolerate at least one statin with this strategy, as recommended by the American College of Cardiology 2
Discontinue the statin until symptoms improve, then rechallenge with a reduced dose, alternative agent, or alternative dosing regimen (including alternate-day dosing), according to the American College of Cardiology 2, 5
Consider pravastatin as first choice for high-risk patients due to lower risk of drug interactions, as noted by the American College of Cardiology 5
Use lower doses of more potent statins (e.g., rosuvastatin at lower doses) if higher potency is needed, according to the American College of Cardiology 5
Avoid high-dose simvastatin due to higher myopathy risk, especially with drug interactions, as recommended by the American College of Cardiology 5
Consider combination therapy with ezetimibe and low-dose statin for patients who cannot tolerate standard doses, according to the American College of Cardiology 5
Continue statin therapy with lifestyle modifications (physical activity, healthy diet, weight loss) if diabetes develops, as recommended by the American College of Cardiology 1, 3

Do NOT routinely measure CK or liver enzymes in asymptomatic patients—this leads to unnecessary discontinuation, as stated by the American College of Cardiology 1, 3
Do NOT discontinue statins if diabetes develops—continue with lifestyle modifications, according to the American College of Cardiology 1, 3
Do NOT attribute all muscle symptoms to statins without evaluating other causes, as noted by the American College of Cardiology 2
Do NOT use coenzyme Q10 for routine prevention or treatment of muscle symptoms—it is not recommended, according to the American College of Cardiology 1, 3
Do NOT avoid statins in patients with stable liver disease—they can be used safely with appropriate monitoring, as